Clinical trial / 2013
Gut-microbiota-dependent TMAO production from dietary phosphatidylcholine was linked to higher risk of major adverse cardiovascular events.
In healthy participants, researchers evaluated TMAO production after a phosphatidylcholine challenge (ingestion of two hard-boiled eggs and d9-labeled phosphatidylcholine) before and after suppression of gut microbiota with oral broad-spectrum antibiotics. They also examined fasting plasma TMAO and major adverse cardiovascular events over 3 years in 4,007 patients undergoing elective coronary angiography. Plasma TMAO levels rose after the challenge, were markedly suppressed after antibiotics, and reappeared after antibiotic withdrawal. In the clinical cohort, increased plasma TMAO levels were associated with higher risk of major adverse cardiovascular events (hazard ratio for highest vs. lowest quartile, 2.54; 95% CI, 1.96 to 3.28; P<0.001), remaining significant after adjustment for traditional risk factors.
- Study type
- Intervention challenge study and prospective cohort study
- Who was studied
- Healthy participants (challenge) and 4,007 patients undergoing coronary angiography
- What was measured
- Plasma TMAO levels and 3-year major adverse cardiovascular events (death, MI, stroke)
THE PAPER
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. N Engl J Med, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.